论文部分内容阅读
目的 观察帕米膦酸二钠联合153Sm -EDTMP治疗骨转移癌的疗效、毒副作用并探讨其临床意义。方法 随机入组 71例骨转移癌患者 ,分别给予帕米膦酸二钠、153Sm -EDTMP以及帕米膦酸二钠联合153Sm -EDTMP治疗 ,对照并观察止痛效果及毒性。结果 帕米膦酸二钠、153Sm -EDTMP以及帕米膦酸二钠联合153Sm -EDTMP组的止痛有效率分别为 67%、67%和 88 5 % ,P >0 .0 5 ,提示全组差异无显著性 ,但以 χ2 分割法检验则联合组与其它单用组之间的差异有显著性 (P <0 .0 5 ) ,而毒副反应无显著性差异。结论 帕米膦酸二钠联合153Sm -EDTMP治疗骨转移癌所致疼痛有更好的疗效
Objective To observe the efficacy, toxicity and side effects of pamidronate combined with 153Sm-EDTMP in the treatment of bone metastases and to explore its clinical significance. Methods A total of 71 patients with metastatic bone cancer were enrolled in this study. Pamidronate disodium, 153Sm-EDTA and pamidronate combined with 153Sm-EDTMP were given respectively. The analgesic effect and toxicity were observed. Results The analgesic efficacies of pamidronate disodium, 153Sm-EDTA and pamidronate combined with 153Sm-EDTMP were 67%, 67% and 88 5%, respectively, P> 0.05, suggesting that the difference between the two groups However, the difference between the combined group and other single groups was significant (P <0.05) by χ2 test, but no significant difference in the side effects. Conclusion Pamidronate combined with 153Sm-EDTMP treatment of bone metastases caused by pain have a better effect